WVE-N531 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04906460 (ClinicalTrials.gov) | September 28, 2021 | 24/5/2021 | Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | An Open-label Phase 1b/2a Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: WVE-N531 | Wave Life Sciences Ltd. | NULL | Recruiting | 5 Years | 12 Years | Male | 15 | Phase 1/Phase 2 | Canada;United Kingdom |